All In Biotech

Drug Trial Radar · NCT03428217

CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial Comparing CB-839 in Combination With Cabozantinib (CB-Cabo) vs. Placebo With Cabozantinib (Pbo-Cabo) in Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC)

Last checked: Nov 19, 2026Latest source record: Mar 20, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 444 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

444

Actual

Start

Apr 24, 2018

Primary completion

Aug 31, 2020

Study completion Jul 16, 2021

Sponsor

Lead sponsor
Calithera Biosciences, IncIndustry
Sponsor type
Industry
First posted
Feb 9, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Tthe primary objective of this study is to compare blinded Independent Radiology Committee (IRC)-adjudicated progression free survival (PFS) of patients treated with CB-839 + cabozantinib (CB-Cabo) versus placebo + cabozantinib (Pbo-Cabo) for advanced or metastatic clear-cell RCC (ccRCC).

Conditions

  • Advanced Renal Cell Carcinoma
  • Metastatic Renal Cell Carcinoma

Interventions

  • CB-839Drug

    Oral glutaminase inhibitor

  • CabozantinibDrug

    Oral receptor tyrosine kinase inhibitor

  • PlaceboDrug

    Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) as Assessed by the Independent Radiology Committee (IRC)Time frame: Up to the primary analysis data cut-off date of 31 Aug 2020. Maximum duration of follow-up for PFS was 22.14 months.

Locations

133 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Cancer Center

    Phoenix, Arizona

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute

    Los Angeles, California

  • Stanford Cancer Center

    Palo Alto, California

  • Salinas Valley Memorial Healthcare System

    Salinas, California

  • St. Joseph Heritage Healthcare

    Santa Rosa, California

  • Penrose Cancer Center, Research Department

    Colorado Springs, Colorado

  • Georgetown University Medical Center

    Washington D.C., District of Columbia

  • Florida Cancer Specialists

    Fort Myers, Florida

  • University of Miami Sylvester Comprehensive Cancer Center

    Miami, Florida

  • Florida Cancer Specialists

    St. Petersburg, Florida

  • H.Lee Moffitt Cancer & Research Institute (Moffitt Cancer Center)

    Tampa, Florida

  • Emory Winship Cancer Institute

    Atlanta, Georgia

  • Georgia Cancer Center at Augusta University

    Augusta, Georgia

  • Northwest Georgia Oncology Centers, PC

    Marietta, Georgia

  • St. Luke's Mountain States Tumor Institute

    Boise, Idaho

  • Northwestern University

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • NorthShore University HealthSystem

    Evanston, Illinois

  • AMITA Health Cancer Institute & Outpatient Center

    Hinsdale, Illinois

  • Orchard Healthcare Research, Inc.

    Skokie, Illinois

  • Northwestern Medicine Cancer Center Warrenville

    Warrenville, Illinois

  • Goshen Center for Cancer Care

    Goshen, Indiana

  • East Jefferson General Hospital

    Metairie, Louisiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • University of Maryland, Greenebaum Comprehensive Cancer Center

    Baltimore, Maryland

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Karmanos Cancer Institute

    Detroit, Michigan

  • HealthPartners Institute, Regions Cancer Care Center

    Saint Paul, Minnesota

  • Hattiesburg Clinic Hematology/Oncology

    Hattiesburg, Mississippi

  • University of Mississippi Medical Center

    Jackson, Mississippi

  • Mercy Hospital

    Joplin, Missouri

  • HCA Midwest Health

    Kansas City, Missouri

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • San Juan Oncology Associates, PC

    Farmington, New Mexico

  • Roswell Park Cancer Center

    Buffalo, New York

  • North Shore Hematology Oncology Associates PC dba NY Cancer and Blood Specialists

    East Setauket, New York

Showing 40 of 133 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.